EyePoint (EYPT) vs Inhibikase Therapeutics (IKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Inhibikase Therapeutics (IKT) has outperformed EyePoint (EYPT) over the past year, gaining 19.8% versus a loss of 74.9%. Over five years, EYPT leads with a -71.0% price change compared with -83.2% for IKT. EyePoint is the larger company by market cap ($290.1 million vs $266.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | IKT |
|---|---|---|
| Share price | $3.46 | $1.91 |
| Market cap | $290.09M | $266.51M |
| 1-day change | +4.22% | -1.55% |
| YTD return | -81.83% | -5.37% |
| 1-year return | -74.94% | +19.75% |
| 5-year return | -70.98% | -83.25% |
| EPS (TTM) | $-3.75 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.11 | $2.61 |
| 52-week low | $3.05 | $1.33 |
| Distance from 52-week high | -81.89% | -26.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +648.84% | +214.14% |
| Average volume | 3.93M | 656.02K |
| Shares outstanding | 83.84M | 139.54M |
| Employees | 214 | 35 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IKT has outperformed EYPT by 94.7 percentage points over the past year.
- The two companies sit in different sectors: EyePoint in Industrials and Inhibikase Therapeutics in Health Care.
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
EYPT vs IKT FAQ
Which is bigger, EyePoint or Inhibikase Therapeutics?
EyePoint (EYPT) is larger, with a market capitalization of $290.09M compared with $266.51M for Inhibikase Therapeutics (IKT).
Which stock has performed better over the past year, EYPT or IKT?
IKT returned +19.75% over the past 12 months, compared with -74.94% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and Inhibikase Therapeutics in the same industry?
No. EyePoint is in the Industrials sector, while Inhibikase Therapeutics is in Health Care.